vs
Clearfield, Inc.（CLFD）与ARS Pharmaceuticals, Inc.（SPRY）财务数据对比。点击上方公司名可切换其他公司
Clearfield, Inc.的季度营收约是ARS Pharmaceuticals, Inc.的1.2倍（$34.3M vs $28.1M），Clearfield, Inc.净利率更高（-1.8% vs -147.1%，领先145.3%），Clearfield, Inc.同比增速更快（-3.2% vs -67.6%）
Clearfield, Inc.总部位于美国明尼苏达州明尼阿波利斯市，是一家专注于光纤产品研发生产的企业，其产品主要应用于光纤通信网络建设领域，为通信基础设施部署提供相关硬件支撑。
ARS Pharmaceuticals是一家处于后期研发阶段的生物制药企业，专注于开发和商业化严重过敏反应创新疗法，核心产品为无需注射的肾上腺素鼻腔递送制剂，主要面向北美市场，服务存在致命过敏风险的成人及儿童患者群体。
CLFD vs SPRY — 直观对比
营收规模更大
CLFD
是对方的1.2倍
$28.1M
营收增速更快
CLFD
高出64.4%
-67.6%
净利率更高
CLFD
高出145.3%
-147.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $34.3M | $28.1M |
| 净利润 | $-614.0K | $-41.3M |
| 毛利率 | 33.2% | — |
| 营业利润率 | -5.3% | -147.6% |
| 净利率 | -1.8% | -147.1% |
| 营收同比 | -3.2% | -67.6% |
| 净利润同比 | 67.8% | -182.8% |
| 每股收益（稀释后） | $-0.04 | $-0.41 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLFDSPRY
| Q4 25 | $34.3M | $28.1M | ||
| Q3 25 | $23.4M | $32.5M | ||
| Q2 25 | $49.9M | $15.7M | ||
| Q1 25 | $47.2M | $8.0M | ||
| Q4 24 | $29.7M | $86.6M | ||
| Q3 24 | $5.6M | $2.1M | ||
| Q2 24 | $48.8M | $500.0K | ||
| Q1 24 | $36.9M | $0 |
净利润CLFDSPRY
| Q4 25 | $-614.0K | $-41.3M | ||
| Q3 25 | $-9.1M | $-51.2M | ||
| Q2 25 | $1.6M | $-44.9M | ||
| Q1 25 | $1.3M | $-33.9M | ||
| Q4 24 | $-1.9M | $49.9M | ||
| Q3 24 | — | $-19.1M | ||
| Q2 24 | $-447.0K | $-12.5M | ||
| Q1 24 | $-5.9M | $-10.3M |
毛利率CLFDSPRY
| Q4 25 | 33.2% | — | ||
| Q3 25 | 53.2% | — | ||
| Q2 25 | 30.5% | — | ||
| Q1 25 | 30.1% | — | ||
| Q4 24 | 29.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 21.9% | — | ||
| Q1 24 | 7.7% | — |
营业利润率CLFDSPRY
| Q4 25 | -5.3% | -147.6% | ||
| Q3 25 | 10.3% | -163.7% | ||
| Q2 25 | 3.0% | -302.9% | ||
| Q1 25 | 0.6% | -466.3% | ||
| Q4 24 | -6.9% | 54.5% | ||
| Q3 24 | — | -1051.6% | ||
| Q2 24 | -4.7% | -3068.0% | ||
| Q1 24 | -26.4% | — |
净利率CLFDSPRY
| Q4 25 | -1.8% | -147.1% | ||
| Q3 25 | -38.8% | -157.4% | ||
| Q2 25 | 3.2% | -285.6% | ||
| Q1 25 | 2.8% | -425.7% | ||
| Q4 24 | -6.4% | 57.7% | ||
| Q3 24 | — | -925.0% | ||
| Q2 24 | -0.9% | -2503.2% | ||
| Q1 24 | -16.0% | — |
每股收益（稀释后）CLFDSPRY
| Q4 25 | $-0.04 | $-0.41 | ||
| Q3 25 | $-0.65 | $-0.52 | ||
| Q2 25 | $0.11 | $-0.46 | ||
| Q1 25 | $0.09 | $-0.35 | ||
| Q4 24 | $-0.13 | $0.52 | ||
| Q3 24 | — | $-0.20 | ||
| Q2 24 | $-0.04 | $-0.13 | ||
| Q1 24 | $-0.40 | $-0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $96.4M | $245.0M |
| 总债务越低越好 | — | $96.4M |
| 股东权益账面价值 | $249.7M | $114.3M |
| 总资产 | $268.1M | $327.7M |
| 负债/权益比越低杠杆越低 | — | 0.84× |
8季度趋势，按日历期对齐
现金及短期投资CLFDSPRY
| Q4 25 | $96.4M | $245.0M | ||
| Q3 25 | $106.0M | $288.2M | ||
| Q2 25 | $117.2M | $240.1M | ||
| Q1 25 | $112.0M | $275.7M | ||
| Q4 24 | $113.0M | $314.0M | ||
| Q3 24 | $129.0M | $204.6M | ||
| Q2 24 | $123.8M | $218.7M | ||
| Q1 24 | $142.9M | $223.6M |
总债务CLFDSPRY
| Q4 25 | — | $96.4M | ||
| Q3 25 | — | $96.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | $2.2M | — | ||
| Q2 24 | $2.1M | — | ||
| Q1 24 | — | — |
股东权益CLFDSPRY
| Q4 25 | $249.7M | $114.3M | ||
| Q3 25 | $256.2M | $147.7M | ||
| Q2 25 | $264.5M | $192.3M | ||
| Q1 25 | $265.9M | $229.0M | ||
| Q4 24 | $267.4M | $256.8M | ||
| Q3 24 | $275.8M | $201.0M | ||
| Q2 24 | $274.6M | $215.2M | ||
| Q1 24 | $279.2M | $223.9M |
总资产CLFDSPRY
| Q4 25 | $268.1M | $327.7M | ||
| Q3 25 | $306.2M | $372.8M | ||
| Q2 25 | $314.7M | $313.5M | ||
| Q1 25 | $310.9M | $327.3M | ||
| Q4 24 | $303.2M | $351.2M | ||
| Q3 24 | $315.3M | $217.6M | ||
| Q2 24 | $318.1M | $222.0M | ||
| Q1 24 | $315.4M | $227.6M |
负债/权益比CLFDSPRY
| Q4 25 | — | 0.84× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | 0.01× | — | ||
| Q2 24 | 0.01× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.4M | $-43.5M |
| 自由现金流经营现金流 - 资本支出 | $-2.4M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 2.9% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CLFDSPRY
| Q4 25 | $-1.4M | $-43.5M | ||
| Q3 25 | — | $-47.0M | ||
| Q2 25 | $7.9M | $-39.6M | ||
| Q1 25 | $3.0M | $-40.7M | ||
| Q4 24 | $7.2M | $42.0M | ||
| Q3 24 | $22.2M | $-14.5M | ||
| Q2 24 | $4.0M | $-7.3M | ||
| Q1 24 | $-5.7M | $-6.7M |
自由现金流CLFDSPRY
| Q4 25 | $-2.4M | — | ||
| Q3 25 | — | $-47.2M | ||
| Q2 25 | $7.5M | $-39.6M | ||
| Q1 25 | $654.0K | $-40.8M | ||
| Q4 24 | $5.1M | $41.7M | ||
| Q3 24 | $18.2M | $-14.6M | ||
| Q2 24 | $2.8M | $-7.3M | ||
| Q1 24 | $-7.7M | $-6.8M |
自由现金流率CLFDSPRY
| Q4 25 | -7.1% | — | ||
| Q3 25 | — | -145.4% | ||
| Q2 25 | 15.1% | -252.2% | ||
| Q1 25 | 1.4% | -512.1% | ||
| Q4 24 | 17.1% | 48.2% | ||
| Q3 24 | 323.0% | -706.3% | ||
| Q2 24 | 5.8% | -1463.4% | ||
| Q1 24 | -20.8% | — |
资本支出强度CLFDSPRY
| Q4 25 | 2.9% | 0.0% | ||
| Q3 25 | 2.0% | 0.6% | ||
| Q2 25 | 0.8% | 0.3% | ||
| Q1 25 | 5.1% | 1.1% | ||
| Q4 24 | 7.0% | 0.3% | ||
| Q3 24 | 71.4% | 6.8% | ||
| Q2 24 | 2.5% | 7.6% | ||
| Q1 24 | 5.3% | — |
现金转化率CLFDSPRY
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 4.93× | — | ||
| Q1 25 | 2.30× | — | ||
| Q4 24 | — | 0.84× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLFD
暂无分部数据
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
